Boston Scientific Corporation $BSX Shares Bought by Machina Capital S.A.S.

Machina Capital S.A.S. grew its holdings in Boston Scientific Corporation (NYSE:BSX) by 119.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 52,194 shares of the medical equipment provider’s stock after purchasing an additional 28,401 shares during the period. Boston Scientific makes up 0.9% of Machina Capital S.A.S.’s investment portfolio, making the stock its 19th largest position. Machina Capital S.A.S.’s holdings in Boston Scientific were worth $5,096,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. State Street Corp grew its stake in shares of Boston Scientific by 1.1% during the second quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock worth $7,002,258,000 after purchasing an additional 713,379 shares in the last quarter. Synergy Asset Management LLC raised its stake in Boston Scientific by 3,493.0% in the third quarter. Synergy Asset Management LLC now owns 493,323 shares of the medical equipment provider’s stock valued at $48,297,000 after buying an additional 479,593 shares in the last quarter. Gladstone Institutional Advisory LLC lifted its holdings in Boston Scientific by 39.5% during the 3rd quarter. Gladstone Institutional Advisory LLC now owns 51,884 shares of the medical equipment provider’s stock worth $5,065,000 after buying an additional 14,700 shares during the last quarter. Channel Wealth LLC boosted its position in shares of Boston Scientific by 70.8% during the 3rd quarter. Channel Wealth LLC now owns 28,577 shares of the medical equipment provider’s stock worth $2,790,000 after acquiring an additional 11,847 shares in the last quarter. Finally, Bank of Nova Scotia boosted its position in shares of Boston Scientific by 106.4% during the 2nd quarter. Bank of Nova Scotia now owns 3,025,519 shares of the medical equipment provider’s stock worth $324,971,000 after acquiring an additional 1,559,605 shares in the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific Stock Down 0.3%

Shares of NYSE:BSX opened at $91.56 on Wednesday. Boston Scientific Corporation has a 1-year low of $85.98 and a 1-year high of $109.50. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.51 and a quick ratio of 0.96. The stock has a market cap of $135.73 billion, a P/E ratio of 48.96, a P/E/G ratio of 1.63 and a beta of 0.67. The firm has a fifty day moving average price of $94.89 and a 200 day moving average price of $99.29.

Insider Activity

In other news, Director Ellen M. Zane sold 12,891 shares of the stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the completion of the sale, the director owned 24,134 shares in the company, valued at approximately $2,371,889.52. This represents a 34.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Michael F. Mahoney sold 160,901 shares of the business’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. This trade represents a 10.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 191,105 shares of company stock valued at $18,067,697. Insiders own 0.50% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently weighed in on BSX. Wall Street Zen raised Boston Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, January 17th. Canaccord Genuity Group cut their price objective on shares of Boston Scientific from $132.00 to $131.00 and set a “buy” rating on the stock in a report on Wednesday, December 17th. Needham & Company LLC restated a “buy” rating on shares of Boston Scientific in a research report on Thursday, January 15th. Wells Fargo & Company upped their target price on shares of Boston Scientific from $124.00 to $125.00 and gave the company an “overweight” rating in a report on Thursday, October 23rd. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Boston Scientific in a research report on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $123.26.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.